Abstract
The prevalence of type 2 diabetes mellitus continues to increase both in the UK and worldwide. There is a continuing need to identify novel therapeutic agents that offer improved efficacy and safety over existing anti-diabetic treatments. An increased understanding of the incretin hormone pathway has been the catalyst for development of two new classes of drugs: the DPP-4 inhibitors (gliptins) and the GLP-1 agonists (incretin mimetics). This article provides a summary of when and how to use these agents.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
